Holen Sie sich die Stockscreener-App
2.13
4.05%
-0.09
Handel nachbörslich:
2.20
0.07
+3.29%
Schlusskurs vom Vortag:
$2.22
Offen:
$2.24
24-Stunden-Volumen:
130.90K
Relative Volume:
0.76
Marktkapitalisierung:
$56.00M
Einnahmen:
$1.79M
Nettoeinkommen (Verlust:
$-70.90M
KGV:
-0.1371
EPS:
-15.54
Netto-Cashflow:
$-34.95M
1W Leistung:
-4.48%
1M Leistung:
+9.79%
6M Leistung:
-40.17%
1J Leistung:
-65.65%
1-Tages-Spanne:
$2.06
$2.25
1-Wochen-Bereich:
$2.0311
$2.25
52-Wochen-Spanne:
$1.26
$7.10
Senti Biosciences Inc Stock (SNTI) Company Profile
Firmenname
Senti Biosciences Inc
Sektor
Branche
Telefon
(650) 239-2030
Adresse
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Vergleichen Sie SNTI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
2.13 | 58.37M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-06 | Eingeleitet | Laidlaw | Buy |
| 2022-10-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Aktie (SNTI) Neueste Nachrichten
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Senti Biosciences, Inc. to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented At the American Society of Hematology Annual Meeting 2025 - marketscreener.com
Senti Biosciences, Inc. to Host Conference Call on Updated Clinical Results for SENTI-202 Prior to ASH Annual Meeting - Quiver Quantitative
Senti Bio (Nasdaq: SNTI) to host Dec. 9 webcast on updated SENTI-202 data from ASH 2025 - Stock Titan
How Senti Biosciences Inc. stock reacts to oil pricesJuly 2025 Price Swings & Capital Efficiency Focused Strategies - Newser
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - ADVFN
Form 8-KCurrent report - ADVFN
Check Out Senti Biosciences Inc (SNTI)’s Trade Data Rather Than the Analysts’ Views - Setenews
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $8.75 Consensus PT from Analysts - Defense World
Leerink Partners Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study - MSN
Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating - Investing.com Australia
Leerink Partners Initiates Coverage of Senti Biosciences (SNTI) with Outperform Recommendation - Nasdaq
Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating By Investing.com - Investing.com South Africa
SNTI Stock Rating Update: Leerink Partners Initiates Coverage | - GuruFocus
Why Senti Biosciences Inc. stock is a must watch in 20252025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - newser.com
Is Senti Biosciences Inc. stock vulnerable to regulatory risksJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
Why Senti Biosciences Inc. stock could benefit from AI revolutionWeekly Gains Summary & Technical Entry and Exit Tips - newser.com
Is Senti Biosciences Inc. trending in predictive chart modelsQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
Combining machine learning predictions for Senti Biosciences Inc.Quarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
How Senti Biosciences Inc. stock benefits from global expansionEarnings Risk Summary & Growth Focused Stock Reports - newser.com
Building trade automation scripts for Senti Biosciences Inc.2025 Volume Leaders & Weekly Momentum Picks - newser.com
Will Senti Biosciences Inc. stock recover faster than peersEarnings Recap Report & Technical Analysis for Trade Confirmation - newser.com
Is Senti Biosciences Inc. forming a reversal patternJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Will a bounce in Senti Biosciences Inc. offer an exitEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
Bicara Therapeutics (NASDAQ:BCAX) versus Senti Biosciences (NASDAQ:SNTI) Head to Head Analysis - Defense World
Finanzdaten der Senti Biosciences Inc-Aktie (SNTI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.44%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):